| Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes M Sobral-Leite, I Salomon, M Opdam, DT Kruger, KJ Beelen, ... Breast Cancer Research 21 (1), 1-12, 2019 | 101 | 2019 |
| PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in … K Beelen, M Opdam, TM Severson, RHT Koornstra, AD Vincent, ... Breast Cancer Research 16 (1), 1-10, 2014 | 76 | 2014 |
| Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo) adjuvant systemic therapy VMT de Jong, Y Wang, ND Ter Hoeve, M Opdam, N Stathonikos, ... Journal of clinical oncology 40 (21), 2361, 2022 | 72 | 2022 |
| High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer PC Schouten, MA Vollebergh, M Opdam, M Jonkers, M Loden, ... Molecular cancer therapeutics 15 (1), 190-198, 2016 | 59 | 2016 |
| Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment K Beelen, M Opdam, TM Severson, RHT Koornstra, AD Vincent, ... Breast cancer research 16, 1-10, 2014 | 58 | 2014 |
| CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment K Beelen, M Opdam, TM Severson, RHT Koornstra, AD Vincent, ... Breast cancer research and treatment 139, 649-655, 2013 | 44 | 2013 |
| Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology images SC Wetstein, VMT de Jong, N Stathonikos, M Opdam, GMHE Dackus, ... Scientific Reports 12 (1), 15102, 2022 | 42 | 2022 |
| EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy J Puppe, M Opdam, PC Schouten, K Jóźwiak, E Lips, T Severson, ... Clinical Cancer Research 25 (14), 4351-4362, 2019 | 40 | 2019 |
| 4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer T De Marchi, NQ Liu, C Stingl, MA Timmermans, M Smid, MP Look, ... Molecular oncology 10 (1), 24-39, 2016 | 40 | 2016 |
| PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy K Beelen, LDC Hoefnagel, M Opdam, J Wesseling, J Sanders, AD Vincent, ... International journal of cancer 135 (5), 1257-1263, 2014 | 30 | 2014 |
| 159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study … VMT De Jong, Y Wang, M Opdam, N ter Hoeve, K Jóźwiak, M Hauptmann, ... Annals of Oncology 31, S303, 2020 | 29 | 2020 |
| Comparative cistromics reveals genomic cross-talk between FOXA1 and ERα in tamoxifen-associated endometrial carcinomas M Droog, E Nevedomskaya, Y Kim, T Severson, KD Flach, M Opdam, ... Cancer research 76 (13), 3773-3784, 2016 | 29 | 2016 |
| Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer T De Marchi, AM Timmermans, M Smid, MP Look, C Stingl, M Opdam, ... Oncotarget 7 (3), 3098, 2016 | 29 | 2016 |
| Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus … L de Boo, A Cimino-Mathews, Y Lubeck, A Daletzakis, M Opdam, ... European Journal of Cancer 127, 240-250, 2020 | 28 | 2020 |
| IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer DT Kruger, X Alexi, M Opdam, K Schuurman, L Voorwerk, J Sanders, ... International journal of cancer 146 (8), 2348-2359, 2020 | 25 | 2020 |
| Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences DT Kruger, KJ Beelen, M Opdam, J Sanders, V van der Noort, E Boven, ... British journal of cancer 119 (7), 832-839, 2018 | 25 | 2018 |
| Targeted MS assay predicting tamoxifen resistance in estrogen-receptor-positive breast cancer tissues and sera T De Marchi, E Kuhn, LJ Dekker, C Stingl, RBH Braakman, M Opdam, ... Journal of proteome research 15 (4), 1230-1242, 2016 | 24 | 2016 |
| SRC3 phosphorylation at serine 543 is a positive independent prognostic factor in ER-positive breast cancer W Zwart, KD Flach, B Rudraraju, TMA Abdel-Fatah, O Gojis, S Canisius, ... Clinical Cancer Research 22 (2), 479-491, 2016 | 24 | 2016 |
| Endonuclease FEN1 Coregulates ERα activity and provides a novel drug Interface in Tamoxifen-resistant breast Cancer KD Flach, M Periyasamy, A Jadhav, D Dorjsuren, JC Siefert, TE Hickey, ... Cancer research 80 (10), 1914-1926, 2020 | 23 | 2020 |
| mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma S Stelloo, J Sanders, E Nevedomskaya, J de Jong, D Peters, ... Oncotarget 7 (22), 32916, 2016 | 19 | 2016 |
